The Effect of SGLT2 Inhibitor Dapagliflozin on BMI in Female Adolescents with Type 1 Diabetes

被引：0
|
作者：
Roman, R. [1 ]
Valdivia, N. [2 ]
Ruiz, S. [3 ]
机构：
[1] Univ Antofagasta, Hosp Reg Antofagasta, Antofagasta, Chile
[2] Univ Antofagasta, Antofagasta, Chile
[3] Hosp Reg Antofagasta, Antofagasta, Chile
来源：
HORMONE RESEARCH IN PAEDIATRICS | 2015年 / 84卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
O15
引用
下载
收藏
页码：13 / 13
页数：1
相关论文
共 50 条
  • [31] SGLT2 inhibitor shows promise in type 2 diabetes
    Nature Reviews Drug Discovery, 2010, 9 (3) : 182 - 182
  • [32] SGLT2 Inhibition by Dapagliflozin Attenuates Diabetic Ketoacidosis in Mice with Type-1 Diabetes
    Chen, Huan
    Birnbaum, Yochai
    Ye, Regina
    Yang, Hsiu-Chiung
    Bajaj, Mandeep
    Ye, Yumei
    CARDIOVASCULAR DRUGS AND THERAPY, 2022, 36 (06) : 1091 - 1108
  • [33] SGLT2 Inhibition by Dapagliflozin Attenuates Diabetic Ketoacidosis in Mice with Type-1 Diabetes
    Huan Chen
    Yochai Birnbaum
    Regina Ye
    Hsiu-Chiung Yang
    Mandeep Bajaj
    Yumei Ye
    Cardiovascular Drugs and Therapy, 2022, 36 : 1091 - 1108
  • [34] Case History: Forxiga™ (Dapagliflozin), a Potent Selective SGLT2 Inhibitor for Treatment of Diabetes
    Washburn, William N.
    ANNUAL REPORTS IN MEDICINAL CHEMISTRY, VOL 49, 2014, 49 : 363 - 382
  • [35] SGLT2 IN TYPE 1 DIABETES - EFFICACY
    Mathieu, C.
    DIABETES TECHNOLOGY & THERAPEUTICS, 2020, 22 : A6 - A6
  • [36] Exposure-efficacy outcome modeling for dapagliflozin, an orally selective SGLT2 inhibitor, in patients with type 2 diabetes
    Feng, Yan
    Zhang, Liping
    List, James F.
    Pfister, Marc
    JOURNAL OF CLINICAL PHARMACOLOGY, 2008, 48 (09): : 1114 - 1114
  • [37] Treatment with SGLT2 inhibitor dapagliflozin for non-alcoholic steatohepatitis patients complicated with type 2 diabetes mellitus
    Tobita, Hiroshi
    Sato, Shuiti
    Miyake, Tatuya
    Yazaki, Tomotaka
    Isoda, Kazuki
    Mishiro, Tuyoshi
    Ishihara, Shunji
    Kinoshita, Yoshikazu
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2016, 31 : 388 - 388
  • [38] Efficacy and safety of dapagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in diabetes mellitus
    Paola Fioretto
    Andrea Giaccari
    Giorgio Sesti
    Cardiovascular Diabetology, 14
  • [39] Efficacy and safety of dapagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in diabetes mellitus
    Fioretto, Paola
    Giaccari, Andrea
    Sesti, Giorgio
    CARDIOVASCULAR DIABETOLOGY, 2015, 14
  • [40] Suppression of Ketogenesis in Type 1 Diabetes Is Not Delayed by SGLT2 Inhibitor Therapy
    Siebel, Stephan
    Patel, Neha S.
    Galderisi, Alfonso
    Carria, Lori R.
    Tamborlane, William V.
    Sherr, Jennifer
    DIABETES, 2018, 67
12345